Maria La Mantia

MD, Medical Oncology Resident PhD Student University of Palermo Research Fellow SHRO TempleU, Philadelphia, PA.

[Tom Powles @tompowles1]

Talapro-2 ⬆️ rPFS for talazoparib/enza in unselected CRPC with more benefit in HRR as with olaparib/abi. Titron-3 showed rucaparib alone ⬆️ rPFS, particularly in BRCAs. ATM fails to enrich again. OS not +ve yet in either. The biomarker is important for PARPi in CRPC IMO #ASCOGU23

[Maria La Mantia @MKClementine]

Congrats!!! @ChristianRolfo 👏🏻👏����👏🏻

[Alessandro Russo @Al3ssandroRusso]

Congrats to my dear friend @ChristianRolfo for being elected as member of the academia de ciencias médicas 🇦🇷 Well deserved! @isliquidbiopsy

[Elham Sajjadi @elham_sajjadi]

So honoured to share our work on the tumor immune microenvironment and risk profile analysis of pregnancy associated #breastcancer @Cells_MDPI.
Many 🙏 @NicolaFuscoMD
@KonVenetis @fedrophd & all others. @policlinico @IEOufficiale @LaStatale @4oncommunity
https://t.co/3zA5ci7xQy

[Ruth O'Regan @oreganruth]

Outstanding and thoughtful keynote by Dr. Kaelin day 1 of MCCR22 ⁦@ASCO⁩ ⁦@AACR⁩

[David Gandara @drgandara]

Another targeted therapy enroute to join the therapeutic armamentarium in an oncogene-driven NSCLC subset: FDA Grants Breakthrough Designation to Repotrectinib for Pretreated, ROS1+ Metastatic NSCLC https://t.co/GpOA7Mm0ne via @onclive

[Maria La Mantia @MKClementine]

🎉👏🏻👏🏻👏🏻 #UNIPA #Springer @dichirons

[Antonio Russo @antoniorusso_pa]

Ieri alla Camera dei Deputati ho presentato insieme alla prof.ssa Lorena Incorvaia il “Practical Medical Oncology Textbook”, nuovo libro di Oncologia Medica che da vanto a UNIPA a livello internazionale! Fondamentale il contributo degli editors @ChristianRolfo @ Marc Peeters 🎉

[IASLC @IASLC]

A simple low-dose CT scan can find lung cancer early—when it’s easier to treat and more likely to be cured. RT to share! https://t.co/12y36xksCe #LCAM #LCSM

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

Chi può ammalarsi di tumore del polmone? Tutti!
Ma non è un tumore esclusivo dei fumatori? Assolutamente No!

Novembre è il mese per la sensibilizzazione sul tumore del polmone, parlarne serve! E va fatto!

#LCSM #LCAM #tumore #polmone

[Maria La Mantia @MKClementine]

Congrats on such an extraordinary presentation to my friend @VGristina at the AIOM Giovani Meeting 2021! Such a great orator! You totally rocked it ! NGS is the key 🎉🧬👏🏻☄️ #AIOM #NSCLC #nonEGFRoncogeneAddictedTumors

[Valerio Gristina @VGristina]

Such a massive Mentor 💎#WCLC2021 @UmbertoMalapel1 @isliquidbiopsy @IASLC

[Stéphane TERRY, PhD @StephaneTERRY1]

Interesting review by Saldana C. et al. on #ExtracellularVesicles in Advanced #ProstateCancer @TRePCa3: https://t.co/vuem2BDGGf #mdpicancers via @Cancers_MDPI

[OncLive.com @OncLive]

Although the predictive utility of minimal residual disease has yet to be fully realized in NSCLC, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting @drgandara @UCDavisHealth @IASLC #ILLCC2021 https://t.co/PNSF0X9fPz

[JTO & JTO CRR @JTOonline]

Pooled analysis of KEYNOTE-001, 010, 024, and 042 by Mansfield et al. showed improved outcomes w/ #pembrolizumab monotherapy vs chemotherapy in pts w/ PD-L1–positive NSCLC w/ brain metastases https://t.co/G8bGM5cBdj @AMansfieldMD @OncologyAdvance #JTOCRR #LCSM @IASLC

[Monica Niger @Mom_enji]

Long-awaited and very interesting results! A great step in the HER2 & BTC story. Can’t wait to see what’s next

[Maria La Mantia @MKClementine]

Check out our new paper "Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups" @VGristina @antoniorusso_pa @galvano_antonio https://t.co/6Wkyi0hU9C

[Maria La Mantia @MKClementine]

@fedenichetti That s not unexpected!

[Maria La Mantia @MKClementine]

Congratulations for this big achievement ⁦@VGristina⁩! Such a great teamwork ⁦@UmbertoMalapel1⁩ 💥🎉🤙🏻💪🏻⁦@PasqualePisapia⁩ ⁦@antoniorusso_pa⁩ ad maiora!🎉 #oncology #TMB #NSCLC #bestpaperaward #Dichirons #unipa

[Christian Rolfo @ChristianRolfo]

Despite the great data on targeted therapy 🎯 testing it’s still a big barrier! Only 50% of NSCLC patients are testing for ALK ROS1 BRAF EGFR (and PDL1)It’s not acceptable. Certainly higher in other world regions Equal test access its mandatory!@isliquidbiopsy #ASCO21 @lcsmchat

[Maria La Mantia @MKClementine]

Check out our last paper on concurrent EGFR alteration! What a great team!🎉🤙🏻🔥@antoniorusso_pa @VGristina @galvano_antonio @FedericaIacono5 @chiara_lisanti

[Valerio Gristina @VGristina]

Molecular Pathology meets Medical Oncology: our take on the EGFR double trouble in NSCLC 🚨🔎 @MKClementine @galvano_antonio @antoniorusso_pa @JMP_MDPI @OncoAlert @UmbertoMalapel1